Science of Psychiatric Drugs

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

In the first systematic review of withdrawal problems that patients experience when trying to get off SSRI antidepressant medications, researchers found that withdrawing from SSRIs was comparable to trying to quit addictive benzodiazepines.

Lancet Psychiatry, a UK-based medical journal, recently published a study that concluded brain scans showed that individuals diagnosed with ADHD had smaller brains. That conclusion is belied by the study data. The journal needs to retract this study. UPDATE: Lancet Psychiatry (online) has published letters critical of the study, and the authors' response, and a correction.

Service users taking drugs to treat ADHD may be at increased risk for hypertension and arterial disease

After a meta-analysis of RCTs of antidepressants was published in Lancet, psychiatry stated that it proved that "antidepressants" work. However, effectiveness studies of real-world patients reveal the opposite: the medications increase the likelihood that patients will become chronically depressed, and disabled by the disorder.

The FDA has finally acknowledged the adverse effects of benzodiazepines, the dangers of withdrawal, and that the current packaging does not sufficiently warn of these harms.

Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

Researchers can’t predict the 15% who benefit from antidepressants, and the other 85% are unnecessarily exposed to the harms of the drugs.

At the Hurdalsjøen Recovery Center in Norway, patients with a long history of psychiatric hospitalizations are tapering from their medications and, in a therapeutic environment that emphasizes a good diet, exercise, and asking patients "what do they want in life," are leaving their old lives as chronic patients behind.

Study reveals schizophrenia patients find little support from mental health staff in reducing side effects-heavy drugs.

During the past twenty years, the American Foundation for Suicide Prevention and American psychiatry have adopted a "medicalized" approach to preventing suicide, claiming that antidepressants are protective against suicide. Yet, the suicide rate in the United States has increased 30% since 2000, a time of rising usage of antidepressants. A review of studies of the effects of mental health treatment and antidepressants on suicide reveals why this medicalized approach has not only failed, but pushed suicide rates higher.

Nassir Ghaemi: “Most psychiatric medications are purely symptomatic, with no known or proven effect on the underlying disease. They are like 50 variations of aspirin, used for fever or headache, rather than drugs that treat the causes of fever or headache.”

A new study, published in the JAMA Psychiatry, investigates the effect of stimulant ‘ADHD’ drugs on the brains of children and young adults. The...

A review of the scientific literature related to withdrawal from antidepressants: mechanism of action; long-term effects of exposure to antidepressants; discontinuation syndromes; relapse upon discontinuation; tapering protocols.

A new study conducted by Jeffrey Vittengl at Truman University has found that taking antidepressant medications resulted in more severe depression symptoms after nine years.

In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.

Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

Results from a 30-year prospective study demonstrated worse outcomes for people who took antidepressants, even after controlling for gender, education level, marriage, baseline severity, other affective disorders, suicidality, and family history of depression.

Research undermines the prolonged use of antipsychotics in schizophrenia treatment, suggesting improved social functioning and quality of life with discontinuation.

People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

For the past 15 years, the VA's suicide prevention efforts have focused on getting veterans screened and treated for psychiatric disorders, with antidepressants a first-line therapy. This effort has caused veteran suicide rates to steadily rise.

Those who did not get antipsychotics in the first month were almost twice as likely to be in recovery after five years.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.